Cooper Companies ((COO)) has held its Q1 earnings call. Read on for the main highlights of the call.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Cooper Companies’ latest earnings call struck a notably upbeat tone, with management leaning on strong execution, a sizable earnings beat and rising free cash flow to justify raising guidance. While pockets of weakness in Asia Pacific, fertility and Paragard weighed on growth, the message was that these headwinds are temporary and outweighed by product strength, efficiency gains and disciplined capital deployment.
Steady Top-Line Growth Across the Portfolio
Consolidated revenue reached $1.024 billion, up 6.2% year over year, with organic growth of 2.9% despite regional and product-specific pressures. The company framed this as a solid start to the fiscal year, particularly given currency, tariff and geographic headwinds that muted reported organic momentum.
Segment Performance: Vision Outpaces Surgical
CooperVision remained the growth workhorse, delivering $695 million of revenue, up 7.6% with 3.3% organic expansion. CooperSurgical added $329 million, growing 3.3% with 2.2% organic growth, as improving fertility trends were partially offset by regional softness and a decline in Paragard.
EPS Surge and Margin Efficiency
Non‑GAAP EPS jumped 20% to $1.10, well ahead of prior expectations, as margin execution more than offset modest revenue shortfalls in certain regions. Gross margin reached 68.1%, helped by a lighter mix of lower‑margin Asia Pacific revenue, while operating income climbed nearly 13.9% and opex fell to 41.2% of sales from 43.6%.
Free Cash Flow Fuels Buybacks and Deleveraging
Free cash flow came in at $159 million for the quarter, giving management confidence to raise its multi‑year outlook and step up capital returns. Cooper spent $92 million to repurchase 1.1 million shares and trimmed net debt to $2.4 billion, signaling a balanced focus on shareholder returns and balance sheet health.
Higher Earnings Bar for Fiscal 2026
On the back of the Q1 beat and efficiency gains, Cooper lifted its fiscal 2026 non‑GAAP EPS guidance to a range of $4.58 to $4.66. Management stressed that the improved earnings outlook reflects both durable cost synergies and confidence in product-driven growth rather than one‑off benefits.
MyDay and MiSight Lead Product Momentum
Product commentary centered on the strength of premium daily lenses, with silicone hydrogel dailies growing 7% and the MyDay portfolio posting double‑digit gains. Key MyDay SKUs, including multifocal, Energys and toric lenses, each rose more than 15%, while MiSight, used for myopia control, surged 23% to $28 million, aided by early traction in Europe and Japan.
Market Share Gains Extend Long-Running Streak
CooperVision continued to outgrow the broader contact lens market, increasing revenue 10% in calendar Q4 against market growth of 6%. For calendar 2025 to date, CooperVision is up 6% versus 5% for the market, marking an impressive 18 consecutive years of share gains and reinforcing its leadership in specialty and daily lenses.
Synergies, IT and AI Drive Operating Leverage
Management highlighted ongoing benefits from corporate reorganization, IT upgrades and the deployment of AI-enabled tools across operations. These investments are yielding tangible cost efficiencies and better working capital management, freeing up resources to reinvest into sales and marketing to support growth brands like MyDay and MiSight.
Asia Pacific and Japan Weigh on Near-Term Growth
Asia Pacific revenue declined 4%, pressured by softness in Japan tied to lower‑margin legacy hydrogel products rather than core premium offerings. The company expects the region to remain under pressure in the second quarter but return to growth in fiscal Q3 as the product mix normalizes and comparisons ease.
CooperVision Organic Growth Misses Prior Hopes
Despite solid headline growth, CooperVision’s 3.3% organic increase in Q1 fell short of management’s earlier implied target of roughly 4.3%. The gap was largely attributed to weaker legacy hydrogel shipments in Japan and timing issues, which management characterized as transitory rather than indicative of demand erosion.
Fertility and Paragard Face Regional and Product Pressures
Within CooperSurgical, fertility trends improved overall but encountered softness in the Middle East and fewer equipment installations, underscoring exposure to geopolitical risk in that region. Paragard volume declined 7% in the quarter, adding another drag to growth, although management suggested these issues are manageable within the broader portfolio.
Tariffs and FX Add Macro Friction
Cooper is planning for about $24 million in tariffs this year, a cost that management is factoring into pricing and efficiency efforts. Recent dollar strength also led the company to trim its revenue outlook modestly, removing roughly $6 million from Vision and $1 million from Surgical assumptions to reflect less favorable currency.
Elevated Legal and Mix-Related Margin Watchpoints
Legal-related addbacks totaled about $6.7 million, running somewhat higher than recent quarters and flagged as a non-structural item. The company also reminded investors that its large private-label business, historically around one‑third of sales, can place mild pressure on gross margin as new contracts ramp, even though operating margins remain comparable.
Guidance: Revenue Steady, Earnings and Cash Flow Higher
Looking ahead, Cooper kept its consolidated revenue outlook largely unchanged at $4.30 to $4.35 billion, implying organic growth of roughly 4.5% to 5.5% across Vision and Surgical. It raised non‑GAAP EPS guidance to $4.58 to $4.66 and now expects fiscal 2026 free cash flow of $600 to $625 million, with cumulative 2026–2028 free cash flow projected to exceed $2.2 billion under assumptions that include $24 million in tariffs, about $85 million of interest expense and a 15% to 16% tax rate.
Overall, Cooper Companies presented a story of solid growth, expanding margins and strengthening cash generation, tempered by manageable regional and product-specific issues. For investors, the key takeaways were sustained market share gains in Vision, rising earnings power supported by operational synergies and increased confidence in multi‑year free cash flow, even as management navigates tariffs, FX volatility and localized demand weakness.